The European Commission Grants Marketing Authorization for VUMERITY® (diroximel fumarate) as Oral Treatment for Relapsing-Remitting Multiple Sclerosis
16 nov. 2021 09h20 HE
|
Biogen Inc.
VUMERITY is a next-generation oral fumarate treatment for people with relapsing-remitting MS with established efficacy and well-characterized safety, building on Biogen’s leadership in MS oral...
Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research & Development
15 nov. 2021 19h44 HE
|
Biogen Inc.
CAMBRIDGE, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today that Alfred “Al” W. Sandrock, Jr., M.D., Ph.D., Head of Research & Development, will retire from...
Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year
15 nov. 2021 07h30 HE
|
Biogen Inc.
Biogen earns top ESG leadership scores on areas including Innovation Management and Climate Strategy, highlighting efforts to address urgent and long-term challenges facing humanityIn 2021, Biogen...
New Phase 3 Data Show Positive Correlation Between ADUHELM™ Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer’s Disease
11 nov. 2021 17h10 HE
|
Biogen Inc.
In a pre-specified analysis, ADUHELM significantly lowered plasma p-tau181, a biomarker of the hallmark tau tangles in Alzheimer’s disease, in both Phase 3 trials in a dose- and time-dependent manner...
Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
03 nov. 2021 07h30 HE
|
Biogen Inc.
Late breaker will show ADUHELM™ effect on plasma pTau181 reduction, and its correlation with amyloid beta and slowing cognitive and functional decline.Additional phase 3b late breaker data will shed...
Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS
17 oct. 2021 16h20 HE
|
Biogen Inc.
In the Phase 3 VALOR study, the primary endpoint as measured by the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) did not reach statistical significance; however, signs of...
Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS to be Presented at the American Neurological Association Annual Meeting
14 oct. 2021 16h06 HE
|
Biogen Inc.
CAMBRIDGE, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced topline results from its pivotal Phase 3 VALOR study of tofersen (BIIB067), an investigational...
New Data at ECTRIMS 2021 Highlight Biogen’s Focus on Patient-Centered Outcomes and Improving the MS Patient Experience
13 oct. 2021 06h05 HE
|
Biogen Inc.
Full analysis of Phase 3b NOVA study provides insights on efficacy of every six-week dosing with natalizumab as compared to the approved every four-week dosingReal-world analysis shows significantly...
New MS PATHS Data at ECTRIMS 2021 Confirm Biogen’s Disease-Modifying Therapies Do Not Reduce Antibody Response to COVID-19 Vaccines in People with Multiple Sclerosis
13 oct. 2021 06h02 HE
|
Biogen Inc.
MS PATHS data indicate that 100 percent of people with MS treated with natalizumab, interferons or fumarates achieved an antibody response following COVID-19 vaccinationData from this analysis also...
Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
21 sept. 2021 08h30 HE
|
Biogen Inc.
33 early and late-stage clinical programs across modalities and innovative discovery platformsUniquely positioned to lead in Alzheimer’s disease with ADUHELM® (aducanumab-avwa) and industry-leading...